Table 1 Summary of EN inhibitor IC50, Kd, and retrotransposition efficiency values
Name | IC50 (μM) | Kd (μM) | Retrotransposition efficiency (%) |
|---|---|---|---|
AD2 | 104.0 ± 8.8 | 82.9 ± 34.5 | 50 µM: 98.0 ± 22.9 |
AD3 | 114.4 ± 22.7 | 11.9 ± 7.9 | 20 µM: 59.0 ± 22.4 |
AD5 | 16.1 ± 5.4 | 1.4 ± 0.2 | 10 µM: 89.7 ± 14.0 |
AD7 | 866.4 ± 249.3 | 230.4 ± 60.2 | 20 µM: 42.2 ± 23.9 |
AD9 | 468.2 ± 117.8 | 5.9 ± 2.5 | 50 µM: 21.9 ± 10.9 |
AD11 | 4.0 ± 1.2 | 11.3 ± 7.4 | 50 µM: 52.2 ± 14.4 |
AD12 | 671.2 ± 139.6 | 755.7 ± 398.7 | 50 µM: 17.7 ± 1.9 |
AD13 | 25.0 ± 4.9 | 22.5 ± 11.2 | 20 µM: 75.4 ± 30.7 |
AD14 | 6.0 ± 1.7 | 23.0 ± 9.5 | 25 µM: 71.6 ± 10.4 |
AD16 | 5.8 ± 1.0 | 9.6 ± 1.8 | 25 µM: 59.2 ± 21.7 |
AD17 | 46.6 ± 7.3 | 41.4 ± 13.0 | 5 µM: 94.8 ± 15.8 |
AD18 | 76.3 ± 8.5 | 6.8 ± 2.8 | 10 µM: 92.2 ± 16.4 |
AD28 | 420.7 ± 30.9 | 14.7 ± 3.7 | Toxicity at 2.5 μM |
AD29 | 28.8 ± 3.2 | 139.5 ± 42.2 | 50 µM: 85.8 ± 7.9 |
AD32 | 458.7 ± 82.6 | N.D. | 25 µM: 35.1 ± 16.5 |
AD34 | 12.5 ± 4.2 | 1.8 ± 0.4 | 25 µM: 104.3 ± 7.8 |
AD36 | 865.7 ± 300.1 | 242.9 ± 36.9 | 25 µM: 42.9 ± 22.2 |
AD41 | 514.2 ± 156.1 | N.D. | 25 µM: 129.4 ± 12.0 |
AD43 | 722.2 ± 135.3 | 516.4 ± 44.0 | 50 µM: 57.3 ± 9.0 |
AD50 | 290.6 ± 13.0 | 207.6 ± 42.7 | 25 µM: 100.5 ± 15.0 |